索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]沈佳佳,李天亮.无症状重度主动脉瓣狭窄的治疗及预后[J].国际心血管病杂志,2024,02:89-92.
点击复制

无症状重度主动脉瓣狭窄的治疗及预后(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
89-92
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
沈佳佳; 李天亮
030001 太原，山西医科大学医学影像学院（沈佳佳）；030024 太原，山西省心血管病医院超声科（李天亮）
Author(s):
-
关键词:
重度主动脉瓣狭窄; 无症状; 预后
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.007
文献标识码:
-
摘要:
主动脉瓣狭窄（AS）最有效的治疗是行主动脉瓣置换术，重度AS（SAS）的手术指征是出现临床症状。然而，对于无症状SAS患者，其心脏的结构和功能可能已有损害，由于早期筛查困难，可能错过最佳手术时间，预后差。该文介绍无症状SAS的诊断、治疗及预后。
Abstract:
-

参考文献/References

[1] Otto CM, Prendergast B. Aortic-valve stenosis—from patients at risk to severe valve obstruction[J]. N Engl J Med, 2014, 371(8):744-756.
[2] Eveborn GW, Schirmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis. the Troms? study[J]. Heart, 2013, 99(6):396-400.
[3] Généreux P, Stone GW, O'Gara PT, et al. Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis[J]. J Am Coll Cardiol, 2016, 67(19):2263-2288.
[4] Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study[J]. J Am Coll Cardiol, 2013, 62(11):1002-1012.
[5] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632.
[6] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J]. Circulation, 2021, 143(5):e35-e71.
[7] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation, 2017, 135(25):e1159-e1195.
[8] Lin SS, Roger VL, Pascoe R, et al. Dobutamine stress Doppler hemodynamics in patients with aortic stenosis: feasibility, safety, and surgical correlations[J]. Am Heart J, 1998, 136(6):1010-1016.
[9] Monin JL, Monchi M, Gest V, et al. Aortic stenosis with severe left ventricular dysfunction and low transvalvular pressure gradients: risk stratification by low-dose dobutamine echocardiography[J]. J Am Coll Cardiol, 2001, 37(8):2101-2107.
[10] Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study[J]. Circulation, 2008, 118(14 Suppl):S234-S242.
[11] Ding Q, Zhang Z, Liu H, et al. Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery[J]. Nat Commun, 2019, 10(1):4202.
[12] Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial)[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(8):834-841.
[13] Dahl JS, Videbaek L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis[J]. Am J Cardiol, 2010, 106(5):713-719.
[14] Rosseb? AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis[J]. N Engl J Med, 2008, 359(13):1343-1356.
[15] Alkhouli M, Zack CJ, Sarraf M, et al. Morbidity and mortality associated with balloon aortic valvuloplasty: a national perspective[J]. Circ Cardiovasc Interv, 2017, 10(5):e004481.
[16] Kang DH, Park SJ, Lee SA, et al. Early surgery or conservative care for asymptomatic aortic stenosis[J]. N Engl J Med, 2020, 382(2):111-119.
[17] Lim WY, Ramasamy A, Lloyd G, et al. Meta-analysis of the impact of intervention versus symptom-driven management in asymptomatic severe aortic stenosis[J]. Heart, 2017, 103(4):268-272.
[18] Henchoz Y, Büla C, Guessous I, et al. Chronic symptoms in a representative sample of community-dwelling older people:a cross-sectional study in Switzerland[J]. BMJ Open, 2017,7(1):e014485.
[19] Vollema EM, Sugimoto T, Shen M, et al. Association of left ventricular global longitudinal strain with asymptomatic severe aortic stenosis: natural course and prognostic value[J]. JAMA Cardiol, 2018, 3(9):839-847.
[20] Goliasch G, Kammerlander AA, Nitsche C, et al. Syncope:the underestimated threat in severe aortic stenosis[J]. JACC Cardiovasc Imaging, 2019, 12(2):225-232.
[21] Redfors B, Pibarot P, Gillam LD, et al. Stress testing in asymptomatic aortic stenosis[J]. Circulation, 2017, 135(20):1956-1976.
[22] Dahl JS, Eleid MF, Michelena HI, et al. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement[J]. Circ Cardiovasc Imaging, 2015, 8(4):e002917.
[23] Bohbot Y, Rusinaru D, Delpierre Q, et al. Risk stratification of severe aortic stenosis with preserved left ventricular ejection fraction using peak aortic jet velocity: an outcome study[J]. Circ Cardiovasc Imaging, 2017, 10(10):e006760.
[24] Magne J, Cosyns B, Popescu BA, et al. Distribution and prognostic significance of left ventricular global longitudinal strain in asymptomatic significant aortic stenosis: an individual participant data meta-analysis[J]. JACC Cardiovasc Imaging, 2019, 12(1):84-92.
[25] Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome[J]. Circulation, 1997, 95(9):2262-2270.
[26] 段同庆, 吴永健, 郑慧娟. 二维斑点追踪成像对无症状重度主动脉瓣狭窄患者危险分层及预后的评估[J]. 临床超声医学杂志, 2019, 21(1):25-28.
[27] Tastet L, Tribouilloy C, Maréchaux S, et al. Staging cardiac damage in patients with asymptomatic aortic valve stenosis[J]. J Am Coll Cardiol, 2019, 74(4):550-563.
[28] Maeder MT, Weber L, Buser M, et al. Pulmonary hypertension in aortic and mitral valve disease[J]. Front Cardiovasc Med, 2018, 5:40.
[29] Steadman CD, Ray S, Ng LL, et al. Natriuretic peptides in common valvular heart disease[J]. J Am Coll Cardiol, 2010, 55(19):2034-2048.
[30] Farré N, Gómez M, Molina L, et al. Prognostic value of NT-proBNP and an adapted monin score in patients with asymptomatic aortic stenosis[J]. Rev Esp Cardiol (Engl Ed), 2014, 67(1): 52-57.
[31] Kvaslerud AB, Santic K, Hussain AI, et al. Outcomes in asymptomatic, severe aortic stenosis[J]. PLoS One, 2021, 16(4):e0249610.
[32] de Lemos JA. Increasingly sensitive assays for cardiac troponins:a review[J]. JAMA, 2013, 309(21):2262-2269.
[33] Lindman BR, Breyley JG, Schilling JD, et al. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement[J]. Heart, 2015, 101(17):1382-1388.
[34] K?hler WM, Freitag-Wolf S, Lambers M, et al. Preprocedural but not periprocedural high-sensitive Troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation[J]. Cardiovasc Ther, 2016, 34(6):385-396.
[35] Solberg OG, Ueland T, Wergeland R, et al. High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis[J]. Scand Cardiovasc J, 2012, 46(5):278-285.

备注/Memo

备注/Memo:
基金项目：国家重点研发计划（2020YFC2008100）
通信作者：李天亮， E-mail：tlli2013@163.com
更新日期/Last Update: 2024-03-25